BENEVICH ERIC 4

What Happened
Eric Benevich, a director of aTYR PHARMA, was granted a derivative award covering 50,000 shares on 2026-05-11. The Form 4 reports the acquisition price as $0.00 (this reflects an option/award rather than a cash purchase) and the award is recorded as a derivative instrument. This is a compensation grant to a non-employee director, not an open-market buy or sale.

Key Details

• Transaction date: 2026-05-11; Form 4 filed 2026-05-13 (filed timely, within the two-business-day Form 4 window).
• Instrument: 50,000-share option award (recorded as a derivative); acquisition price $0.00 on the report.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: The option vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to Mr. Benevich’s continued board service.
• Transaction code: A = Award/Grant (not a purchase P or sale S).

Context
This is a typical non-employee director compensation award and does not represent an immediate purchase or sale of shares. As a derivative (option) award, economic benefit depends on future vesting and any applicable exercise terms; the filing does not show an immediate cashless exercise or sale. Such grants are common and should be viewed as routine compensation unless accompanied by other trading activity.